Andrei Ungureanu

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations

Georgios Tsaousis, Eirini Papadopoulou, Angela Apessos et al. · BMC Cancer · 2019 · 134 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Aging Yeast Cells Undergo a Sharp Entry into Senescence Unrelated to the Loss of Mitochondrial Membrane Potential

Steffen Fehrmann, C Paoletti, Youlian Goulev et al. · Cell Reports · 2013 · 129 citations · Full text

Life Sciences, Biology, Cell Biology +16

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Sherene Loi, Roberto Salgado, Giuseppe Curigliano et al. · Nature Medicine · 2025 · 99 citations · Full text

Medicine, Oncology, Pharmacology +17

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

David R. Spigel, Afshin Dowlati, Yuanbin Chen et al. · Journal of Clinical Oncology · 2024 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15